Currently Viewing:
NCCN 22nd Annual Conference
Dr Moon S. Chen Jr Explains the Far-Reaching Benefits of the California Cancer Registry
June 06, 2017
Currently Reading
Dr Matthew Gubens Outlines Exciting Directions for Lung Cancer Immunotherapy Research
May 20, 2017
Dr Shauntice Allen Discusses Community Engagement in Public Health Research
April 28, 2017
Dr Shaji Kumar Discusses Biological Foundations of New Multiple Myeloma Research
April 24, 2017
Dr Matthew Gubens: Multidisciplinary Approach Can Help Oncologists Tackle Immunotherapy Toxicities
April 21, 2017
Dr Moon S. Chen Jr: Culture and Behavior as Population Determinants of Cancer Outcomes
April 16, 2017
Helping Cancer Patients Quit Smoking Through Counseling and Pharmacotherapy
March 26, 2017
Dr Shauntice Allen Explains Community-Level Factors Contributing to Cancer Disparities
March 25, 2017
Dr Shaji Kumar: Advances and Opportunities in Treating Multiple Myeloma
March 25, 2017
Personalized Care in Lung Cancer Is All About the Molecular Subtype
March 24, 2017
Radiation Therapy Updates for Breast Cancer in the NCCN Guidelines
March 24, 2017
Dr Matthew Gubens Highlights Immunotherapy Advances and Combinations for Lung Cancer
March 23, 2017
Dr Moon S. Chen Jr Discusses Strategies for Reducing Cancer Disparities in Asian Americans
March 23, 2017
Multigene Panels Important for Precision Cancer Care, Variance and Coverage Barriers Remain
March 23, 2017
Addressing the Roots of Disparities in Cancer Care: Inherent Bias, Resources, and Insurance
March 23, 2017

Dr Matthew Gubens Outlines Exciting Directions for Lung Cancer Immunotherapy Research

Matthew Gubens, MD, MS, assistant clinical professor of thoracic oncology at the University of California, San Francisco, discussed the areas of lung immuno-oncology research where he anticipates significant advances will be made in coming years.


Matthew Gubens, MD, MS, assistant clinical professor of thoracic oncology at the University of California, San Francisco, discussed the areas of lung immuno-oncology (IO) research where he anticipates significant advances will be made in coming years.

Transcript (slightly modified)

Are you conducting any ongoing research on lung cancer immunotherapies?

Well, we’re certainly in the hunt of looking at these combination approaches. Certainly, I think one other exciting thing about this area has been the opportunity to work with immunologists who have been in the lab talking about this for years and finally engaging us clinically.

I think some of the interesting efforts we have are to do really sophisticated immuno-profiling. PDL-1 is a biomarker we have, I don’t think any of us think we’ll be using that exclusively 3 years from now. We’re really trying to be more savvy about blood-based biomarkers, proteomics, tumor mutation burden, and really having a sense for both patient selection but also patient follow-up. Do we have early signals of benefit, whether they’re blood-based, whether they’re biopsy-based, or even imaging-based?

I think some of the exciting work is also about PET tracers and may let us have an early sense of benefit, again with the idea of moving a patient off an ineffective treatment to move onto the next thing. So partly combinations, and really being savvy about biomarker development.

The other piece I’m really excited about is looking at a whole other area, looking at folks who have early-stage disease. We know that we’re finding more early-stage disease now that we do more lung cancer screening in at-risk populations, but the idea of maybe using PD-1 inhibition or other IO/IO combinations either neoadjuvantly, which also by the way gives us really nice tissue to work with, or adjuvantly, to see if we can improve cure rates, which is really of course all of our goals in lung cancer. 

 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!